Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | PPIA | P62937 | 2/20 | 0.35 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.34 |
| ▸ | BTK | Q06187 | 1/20 | 0.34 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CTSL | P07711 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.33 |
| ▸ | APLNR | P35414 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1350921 | 0.96 | MAPT (0.47) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL978565 | 0.95 | MAPT (0.50) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL1353132 | 0.95 | MAPT (0.50) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL1820679 | 0.93 | MAPT (0.39) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL5097256 | 0.87 | MAPT (0.34) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL5197158 | 0.86 | MAPT (0.39) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL18482797 | 0.86 | MAPT (0.36) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL387928 | 0.85 | KMT2A (0.39) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL2745968 | 0.85 | USP2 (0.37) | MAPTALDH1A1L3MBTL1MEN1MAPK1 | |
| SCHEMBL2746255 | 0.85 | MAPT (0.35) | MAPTALDH1A1L3MBTL1MEN1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017017630-A1 | NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-02-02 | — | — | WO | disclosed |
| WO-2017017630-A1 | NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS | HETERO RESEARCH FOUNDATION (IN) | 2017-02-02 | — | — | WO | disclosed |
| US-8030309-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-04 | — | — | US | disclosed |
| US-20110015203-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-01-20 | — | — | US | disclosed |
| CN-101400660-A | Triazole derivative or salt thereof | ASTELLAS PHARMA INC (JP) | 2009-04-01 | — | — | CN | disclosed |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | ASTELLAS PHARMA INC. (JP) | 2009-03-26 | — | — | US | disclosed |
| EP-1995243-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-7264792-B2 | Solid phase preparation of 18F-labelled amino acids | GE HEALTHCARE LIMITED (GB) | 2007-09-04 | — | — | US | disclosed |
| EP-1572601-B1 | SOLID-PHASE PREPARATION OF 18 F-LABELLED AMINO ACIDS | GE HEALTHCARE LTD (GB) | 2007-08-15 | — | — | EP | disclosed |
| US-20060039855-A1 | Solid phase preparation of 18f-labelled amino acids | GE HEALTHCARE LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| EP-1572601-A1 | SOLID-PHASE PREPARATION OF 18 F-LABELLED AMINO ACIDS | GE Healthcare Limited (GB) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004056725-A1 | SOLID-PHASE PREPARATION OF 18F-LABELLED AMINO ACIDS | GE HEALTHCARE LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060039855-A1 | Solid phase preparation of 18f-labelled amino acids | SLC7A5, SLC43A1, SLCO2B1 | MAPT 1079/4885ALDH1A1 2918/4885L3MBTL1 1833/4885 |
| US-20110015203-A1 | Viral Polymerase Inhibitors | POLR2A, POLR1E, RPP30 | MAPT 69/4885ALDH1A1 1822/4885L3MBTL1 1210/4885 |
| US-20090082367-A1 | TRIAZOLE DERIVATIVE OR A SALT THEREOF | HSD11B1, HSD11B2, HSD17B1 | MAPT 3869/4885ALDH1A1 389/4885L3MBTL1 1809/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.